Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...
Pfizer Inc. PFE on Tuesday released topline results from its Phase 3 MagnetisMM-32 study evaluating Elrexfio (elranatamab) as ...
Interim data from the open-label phase 3 MagnetisMM-32 study demonstrate a significant progression free survival benefit with elranatamab monotherapy vs active standard regimens in patients previously ...
A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...
Pfizer (PFE) stock is in focus as the company succeeeds in a late-stage trial for multiple myeloma therapy, Elrexfio in an ...
Pfizer Inc. announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received ...
A biologics license application (BLA) for etentamig (ABBV-383) has been submitted to the FDA for the treatment of adults with ...
AbbVie (NYSE: ABBV) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig, a second-generation BCMA x CD3 bispecific ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
Nearly half of patients with multiple myeloma experience pathological fractures, according to a retrospective analysis of 692 ...
Black Americans are more likely to develop multiple myeloma and are often diagnosed at a younger age. The reasons are not fully understood but may involve biological and genetic factors. MGUS, a ...
Metastatic multiple myeloma is a form of cancer of the bone marrow that has spread to other parts of the body. Common sites of metastasis include the skin, muscles, and lymph nodes. Multiple myeloma ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results